Skip to main content

Ureteral Cancer clinical trials at UC Davis
1 research study open to eligible people

  • A Study of Experimental Enfortumab Vedotin versus Chemotherapy For Urothelial Carcinoma (Cancer of the Urinary Tract)

    open to eligible people ages 18 years and up

    The purpose of this study is to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy. This study will also compare progression-free survival on study therapy (PFS1); the overall response rate (ORR) and the disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 of participants treated with EV to participants treated with chemotherapy. In addition, this study will evaluate the duration of response (DOR) per RECIST V1.1 of EV and chemotherapy and assess the safety and tolerability of EV, as well as, the quality of life (QOL) and Patient Reported Outcomes (PRO) parameters.

    Sacramento, California and other locations

Last updated: